You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,501,423


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,501,423
Title:Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
Inventor(s): Albitar; Maher (Sugar Land, TX), Keating; Michael J. (Houston, TX), Manshouri; Taghi (Houston, TX)
Assignee: Board of Regents, The University of Texas System (Austin, TX)
Application Number:13/543,560
Patent Claims:1. A method of monitoring the progress of therapy in patient being treated with a therapeutic anti-CD52 antibody comprising testing a sample from the patient to measure the level of circulating cell-free CD52, circulating cell-free anti-CD52 or circulating cell-free CD52/anti-CD52 complexes.

2. The method of claim 1, wherein the sample is selected from the group consisting of serum, cell lysate and plasma.

3. The method of claim 1, wherein the anti-CD52 antibody is Campath 1H.

4. The method of claim 1, wherein the sample is tested to measure the level of circulating cell-free CD52.

5. The method of claim 1, wherein the sample is tested to measure the level of circulating cell-free anti-CD52.

6. The method of claim 1, wherein the sample is tested to measure the level of circulating cell-free CD52/anti-CD52 complexes.

Details for Patent 8,501,423

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 05/07/2001 ⤷  Try a Trial 2021-09-20
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 11/14/2014 ⤷  Try a Trial 2021-09-20
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 10/12/2004 ⤷  Try a Trial 2021-09-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.